12th Apr 2016 06:46
LONDON (Alliance News) - Hutchison China MediTech Ltd said Tuesday it has initiated the first in-human phase I clinical trial of its compound HMPL-689 in Australia.
This trial will aim to evaluate the safety, tolerability and pharmacokinetics properties of the drug. Following this phase I trial, Hutchison China MediTech plans to investigate HMP-689 in hematological malignancies.
"In pre-clinical studies, not only did HMPL-689 demonstrate a superior potency and better kinase selectivity as compared to drugs in the same class, but it also showed significant efficacy and a favourable safety profile," Hutchison China MediTech said in a statement.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed